Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs

Goli Samimi, Margaret House, Kelly Benante, Lisa Bengtson, Troy Budd, Bridget Dermody, Katina DeShong, Valerie Dyer, Bruce F. Kimler, Vikrant V. Sahasrabuddhe, Suzanne Siminski, Leslie G. Ford, Eduardo Vilar, Eva Szabo

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The COVID-19 pandemic overloaded health care systems around the globe and brought travel restrictions and other mandates. These effects critically impacted cancer care and conduct of clinical trials, and required medical and research communities to incorporate changes and novel flexible work-flows within clinical trials and regulations to improve efficiency. We report the impact of the pandemic on cancer prevention clinical trials managed by the Division of Cancer Prevention within the NCI, focusing on participant-centric, study staff-centric and regulatory elements. Learning lessons from this challenging period, the cancer prevention community has the opportunity to incorporate many of these necessitated novel approaches to future design of clinical trials, to streamline and improve clinical trial efficiency and impact.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalCancer Prevention Research
Volume15
Issue number5
DOIs
StatePublished - May 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs'. Together they form a unique fingerprint.

Cite this